JP Morgan Raises AMRX Price Target to $24
Key Points
- JP Morgan reiterated an Overweight rating on Amneal Pharmaceuticals on October 22, 2026, while bumping its price target up to $24.00 from $22.00.
- JP Morgan's $24 price target implies 17.19% upside from Amneal Pharmaceuticals, Inc.'s ($AMRX) current $20.48 share price.
- The drug maker recently traded at $20.48, sitting about 14.7% below the investment bank's new target and well above both its 50-day and 200-day moving averages.
- Other Wall Street firms have also adjusted their outlooks recently, and the company is preparing to report its next set of earnings on November 3, 2026.
Get Amneal Pharmaceuticals text alerts
We text you when insiders, Congress, analysts or big funds move on $AMRX.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Amneal Pharmaceuticals, Inc. alert may contain errors. Disclosures
JP Morgan reaffirmed its Overweight rating on Amneal Pharmaceuticals, Inc. (NasdaqGS: AMRX) on October 22, 2026, while boosting its price target on the drug maker from $22.00 to $24.00. The research note arrived as part of the bank's ongoing coverage of the specialty and generic pharmaceutical sector.
AMRX
Amneal Pharmaceuticals, Inc.
JP Morgan vs. the S&P 500
Hypothetical returns from JP Morgan's disclosed trades, not real profit or advice. How we model this.
JP Morgan's Call on Amneal Pharmaceuticals
In its October 22 report, JP Morgan kept an Overweight rating on the shares and lifted its target to $24.00 from $22.00. Analyst ratings reflect a firm's forward-looking view on a company's business prospects.
Other Institutional Activity in Amneal Pharmaceuticals
Campbell Newman Asset Management opened a new position of 92,293 shares worth about $1.86 million, according to a filing on October 22, 2026. TPG GP A, LLC held 12,328,767 shares valued at about $252.49 million as of June 30, 2026. Rubric Capital Management LP reduced its holdings by 868,635 shares to end with 10,168,660 shares worth about $208.25 million. Neuberger Berman Group, LLC grew its holdings by 204,743 shares, ending with 3,887,179 shares worth about $79.61 million.
Amneal Pharmaceuticals, Inc. Stock Up 1.4%
Amneal Pharmaceuticals shares recently traded around $20.48, matching their closing price on October 22, 2026. That puts the stock about 9.3% above its 50-day moving average of $18.75 and roughly 32.1% above its 200-day moving average of $15.50. The recent price sits about 3.3% below its 52-week high of $21.18 and up 105.0% from its 52-week low of $9.99. The current trading level is about 11.0% below the broader analyst mean target of $23.00 and 14.7% below JP Morgan's updated target.
$AMRX price target
Amneal Pharmaceuticals, Inc. daily closes and this analyst's $24 target. Not advice.
Recent Earnings
Amneal reported trailing twelve-month revenue of $3.12 billion alongside earnings of $0.49 per share. The company posted a net profit margin of 5.0% and a return on equity of 613.0%. Its next quarterly earnings update is scheduled for November 3, 2026.
Insider Buying and Selling at Amneal Pharmaceuticals, Inc.
Company insiders completed several transactions earlier in the year. Director Deborah M. Autor sold 34,819 shares on May 11, 2026, at an average price of $12.94 for a total value of about $450,558. Officer Nikita Shah sold 146,403 shares on August 12, 2026, at $17.51 per share worth roughly $2.56 million. Officer Jason B. Daly sold 216,613 shares on August 12, 2026, valued at $3.77 million. Director John J. Kiely sold 50,000 shares on August 13, 2026, at $17.64 per share for about $882,000.
Analysts Set New Price Targets
UBS maintained a Buy rating on August 3, 2026, while moving its price target from $23.00 to $25.00. Leerink Partners initiated coverage with an Outperform rating and a $23.00 price target on September 9, 2026. Barclays maintained an Overweight rating on September 17, 2026, raising its target from $16.00 to $20.00. Oppenheimer initiated coverage with an Outperform rating and a $27.00 price target on September 23, 2026. Overall, the stock carries a consensus strong buy rating from seven analysts.
About Amneal Pharmaceuticals
Amneal Pharmaceuticals develops, manufactures, and distributes generic, injectable, biosimilar, and specialty branded medicines. Headquartered in Bridgewater, New Jersey, the global biopharmaceutical company operates through affordable medicines, specialty, and AvKARE segments to supply healthcare markets in the United States and internationally.
Bottom Line
JP Morgan's higher price target points to continued confidence from the bank as Amneal heads toward its upcoming earnings report on November 3, 2026. Investors will be watching the company's financial results and institutional filing updates for further clues on momentum.
Related Filing Alerts
Source: JP Morgan's rating change on $AMRX (Oct 22, 2026). Written by software, not financial advice. How we make alerts